AD-303A
Phase 2Small molecule
AD-303A is one of 10 small molecule programs targeting Androgenetic Alopecia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Androgenetic Alopecia
#DrugCompanyPhaseTrials
1Rogaine
PfizerApproved
Aldactone
PfizerApproved
Propecia
OOrganon and Co
Approved
Depakote
AbbVieApproved
Zyrtec
KKenvue Brands
Approved
Secretome
BBaermed
Phase 2
Lactobacillus Reuteri
TTulane University School of Medicine
Phase 2
AD-303A
MMoogene Medi Co., Ltd
Phase 2
Plasma Derived Exosomes
AAin Shams University
Phase 2
Roxithromycin
HHamamatsu University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AD-303A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMoogene Medi Co., Ltd